Latigo Biotherapeutics Appoints Sara M. Bonstein to Its Board of Directors and as Audit Committee Chair

Key Takeaways

• Sara Bonstein joins Latigo board as independent director
• She will chair Latigo's audit committee
• Bonstein brings over 20 years biotech finance experience
• Raised more than $4 billion across life‑science companies
• Latigo aims to launch non‑opioid pain drug LTG‑001

Pulse Analysis

Latigo’s decision to add Sara M. Bonstein to its board underscores a strategic emphasis on robust corporate governance. As the newly appointed chair of the audit committee, Bonstein will oversee financial reporting, risk management, and compliance at a time when the company is transitioning from early‑stage research to broader clinical execution. Her current role as chief financial officer of Insmed, combined with prior CFO positions at OncoSec Medical and Advaxis, equips her with deep insight into biotech capital structures and regulatory expectations. This governance boost is likely to reassure both existing shareholders and prospective investors.

The non‑opioid pain market has accelerated as regulators and payers push for alternatives to opioid analgesics. Latigo’s lead program, LTG‑001, a selective Nav1.8 inhibitor, targets acute pain without the addiction risk that has plagued the industry for decades. By positioning itself at the forefront of this therapeutic shift, Latigo can capture a sizable share of a market projected to exceed $10 billion globally within the next five years. The board’s enhanced financial oversight will be critical as the company prepares for pivotal Phase II trials and potential partnership discussions.

Bonstein’s track record of raising more than $4 billion across life‑science ventures provides Latigo with a seasoned capital‑raising strategist. Her experience in aligning financial controls with commercial readiness will help streamline budgeting for clinical milestones and accelerate the path to market. Moreover, her Six Sigma Black Belt background suggests a focus on operational efficiency, which can reduce burn rate while preserving R&D momentum. Investors are likely to view the appointment as a signal that Latigo is building the executive infrastructure necessary to translate its scientific promise into commercial success.